Group | Study population | Total N | Mean age ± SD | Female |
|---|
N | % |
|---|
LBD-NP | Low | 263 | 80.84 ± 11.13 | 128 | 48.67 |
Intermediate | 287 | 79.63 ± 10.33 | 163 | 56.79 |
High | 423 | 78.04 ± 7.92 | 268 | 63.36 |
Combined LBD-NP | 973 | 79.27 ± 9.66 | 559 | 57.45 |
PSP | PSP series 1 | 230 | 74.8 ± 7.06 | 105 | 45.65 |
PSP series 2 | 810 | 75.47 ± 7.45 | 376 | 46.42 |
Combined PSP | 1040 | 75.32 ± 7.37 | 481 | 46.25 |
Controls | | 3351 | 80.6 ± 7.1 | 1844 | 55.03 |
- All LBD-NP and PSP participants had neuropathologic diagnosis. Controls had either clinical or neuropathologic diagnosis. “Combined LBD-NP” refers to the combined group of LBD-NP patients from all sub-categories. The sub-categories of “High”, “Intermediate”, or “Low” refers to the likelihood of diagnosing typical clinical DLB-CL based on the 2017 DLB-CL Consortium neuropathologic criteria [17]. All control and a subset of 230 PSP (series 1) cases were genotyped in our prior study [8]. All LBD-NP and an additional 810 PSP cases (series 2) were genotyped in this study
- PSP progressive supranuclear palsy, LBD-NP Lewy body disease, neuropathologic diagnosis
